Evaluation of the effect of VÄ?sÄ?di Kaá¹£Ä?ya over NayopÄ?ya Kaá¹£Ä?ya in the management of Tamaka Å?vÄ?sa W.S.R to Bronchial Asthma â?? A Randomized Open Controlled Clinical Trial - EEVKNKTSBA

Dr Pritali Shetye0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1 Patients of either sex with age between 18 to 60 years.
•2 Newly diagnosed and patients with stable Bronchial Asthma (clinical features of Tamaka Å?vÄ?sa) (as per GINA Guideline) for at least 6 weeks prior to study entry.
•3 Subjects with intermittent & mild persistent controlled bronchial asthma.
•4 FEV1 of < 80% of predicted value.
•5 Patients willing to participate and written consent.

•1 Patients with Status asthmaticus
•2 Patients with evidence of malignancy.
•3 Patients with uncontrolled Diabetes Mellitus of HbA1c >7.5%.
•4 Patients with unstable cardiovascular disease.
•5 Patients suffering from other major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal disorders, etc.)
•6 Patients with concurrent serious hepatic disorder or renal disorders.
•7 Pulmonary disease other than bronchial asthma.
•8 Drug abusers.
•9 H/o hypersensitivity to the trial drug or any of its ingredients.

发起方

Dr Pritali Shetye